Bio

Andy has more than 20 years of experience working in the life sciences industry. His career spans from bench scientist to CEO and he currently serves as a trusted advisor to industry executives. Prior to Deloitte, Andy served as the CEO and founder of SphynKx Therapeutics, an early stage biotechnology company focused on treating kidney disease. Andy began his career as a cancer biologist with Millennium Pharmaceuticals, where he worked on the development of VELCADE®, a blockbuster therapy for the treatment of multiple myeloma. Andy has an MBA from the Darden School of Business at the University of Virginia, in addition to an M.S. in Pharmaceutical Sciences and a B.S. in Molecular Biology, both from the University of Connecticut.